Ibandronate - oral monthly tablets | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (1)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use

Oral ibandronate recovered from an official source; mixed RX page still held

The generic-title BONIVA RX page mixes oral descriptive text with injection dosing content. It is not used to create an oral regimen. A separate official oral-tablet summary is now local.

Before applying: Confirm oral versus intravenous formulation and read the matching local source; do not treat the official addition as recovery of the mixed RX page.

Also check: Oral ibandronate recovered from an official source; mixed RX page still held

Official source

Ibandronate - oral monthly tablets

Product / population: Oral ibandronate tablets for treatment or prevention of postmenopausal osteoporosis; not BONIVA injection.
Renal measure: CrCl, mL/min; estimating equation not specified in the selected renal subsection.

The generic-title GlobalRPh BONIVA destination remains on a mixed-formulation hold. This is a separate official oral source, not an RX recovery.

Renal dosing, restrictions and evidence limits

The labeled oral regimen is 150 mg once monthly on the same calendar date. Use is not recommended at CrCl <30 mL/min. Take at least 60 minutes before food, beverages other than plain water, or other oral medicines and supplements; swallow with 6 to 8 ounces of plain water and remain upright for 60 minutes. The separately stored injection instructions do not apply to these tablets.

Source revision: Prescribing information revised 03/2026. | Retrieved: 2026-09-08. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=86c0b4ae-5e38-4efe-88af-50ac560e294f

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Official product label

Ibandronate - oral monthly tablets

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Oral ibandronate tablets for treatment or prevention of postmenopausal osteoporosis; not BONIVA injection.

Renal method: CrCl, mL/min; estimating equation not specified in the selected renal subsection.
Retrieved: 2026-09-08

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-quality holds

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

Only one eligible source version is stored here. No second source is inferred from a reference link. Independent corroboration is still needed.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

source quality

Oral ibandronate recovered from an official source; mixed RX page still held

The generic-title BONIVA RX page mixes oral descriptive text with injection dosing content. It is not used to create an oral regimen. A separate official oral-tablet summary is now local.

How to use this: Confirm oral versus intravenous formulation and read the matching local source; do not treat the official addition as recovery of the mixed RX page.

Ibandronate - oral monthly tablets Ibandronate injection - BONIVA

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

Official source

Ibandronate - oral monthly tablets

Oral ibandronate tablets for treatment or prevention of postmenopausal osteoporosis; not BONIVA injection.

Method: CrCl, mL/min; estimating equation not specified in the selected renal subsection.

Renal dosing, restrictions and evidence limits Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope Ibandronate - oral monthly tablets

Exact product and population matter. This added page contains locally stored, source-specific clinical summaries. Historical handbook information, when present, is identified separately and may conflict with U.S. labeling. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Locally stored source content

Exact product and population

Product identity selected for the separately displayed source protocols below. Reference: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=86c0b4ae-5e38-4efe-88af-50ac560e294f

Exact product and population

Oral ibandronate tablets for treatment or prevention of postmenopausal osteoporosis; not BONIVA injection.

RDM44-SCOPE-ibandronate-oral-monthly · Source section: Selected source product scopeRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

Ibandronate - oral monthly tablets

Open original reference

Open / share this exact local source

DailyMed / Aurobindo Pharma Limited · Oral ibandronate tablets for treatment or prevention of postmenopausal osteoporosis; not BONIVA injection.

Renal method: CrCl, mL/min; estimating equation not specified in the selected renal subsection.
Source date: Prescribing information revised 03/2026.
Retrieved: 2026-09-08

Restriction or avoidance guidance. Read the specific threshold, age, formulation and dialysis exclusions; do not generalize across products.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

RDM44-official-ibandronate-oral-monthly-c719b1e3b6-C1 · Source locator: Sections 2.1-2.2 and 8.6; PI revised 03/2026; oral tablet product description.

Source-specific limits

The generic-title GlobalRPh BONIVA destination remains on a mixed-formulation hold. This is a separate official oral source, not an RX recovery.

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=86c0b4ae-5e38-4efe-88af-50ac560e294f
Retrieved: 2026-09-08
Exact label title: Ibandronate - oral monthly tablets
DailyMed Set ID: 86c0b4ae-5e38-4efe-88af-50ac560e294f
Labeler: Aurobindo Pharma Limited
Label revision: Prescribing information revised 03/2026.
FDA application: ANDA
Renal-function method: CrCl, mL/min; estimating equation not specified in the selected renal subsection.
Source date/version: Prescribing information revised 03/2026.
Hash meaning: SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256: 227c260f1b7c9d4a52390e55a6b1d16673c898f2fa83b4448d7f13161bf16a0c

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=86c0b4ae-5e38-4efe-88af-50ac560e294f
Source retrieval: 2026-09-08. This is not the source publication or label revision date.
Original source type: source summary
Local text SHA-256: b7e778cc8a2bc4f7e3460cfd5133e4195866ad7175642a8246c84f24b1783d7d
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

This page is an additional exact-product entry, not a recovered GlobalRPh monograph. Its primary scope text and separately attributed clinical summaries are locally included.

Read the full coverage report